You are here
Group President of Global Innovative Pharma and Global Vaccines, Oncology and Consumer Healthcare Businesses
Albert Bourla is the Group President of the Global Innovative Pharma (GIP) and Global Vaccines, Oncology and Consumer Healthcare (VOC) businesses at Pfizer Inc., one of the world’s largest pharmaceutical companies. He is a member of the Company’s Executive Leadership Team.
Pfizer’s Global Innovative Pharma business is focused on the development, registration and commercialization of novel, value-creating medicines. GIP’s broad in-line portfolio includes more than 20 products across six therapeutic areas: inflammation, cardiovascular and metabolic disease, neuroscience and pain, and rare diseases. GIP also includes Pfizer’s Global Health and Value organization which is focused on demonstrating the value of innovation and supports access to Pfizer medicines.
Pfizer Vaccines includes Prevnar 13, the world’s leading pneumococcal vaccine, and a meningitis franchise as well as a promising pipeline of preventative and therapeutic vaccines. Pfizer Oncology is improving the standard of care for cancer patients with products such as Ibrance, Sutent, Xalkori and Inlyta, as well as an extensive pipeline. Pfizer Consumer Healthcare is among the largest over-the-counter health care product businesses in the world with key brands such as Advil, Centrum and Nexium 24HR.
Albert has more than twenty years of experience with Pfizer and has held a number of senior global positions across a range of markets and disciplines. Before assuming his current role, Albert was the Group President of our Global Vaccines, Oncology and Consumer Healthcare Business. Previously, he was President and General Manager of Pfizer’s Established Products Business, where he led the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio (including legacy brands and generics).
Albert joined Pfizer’s Animal Health Division in 1993 as Technical Director of Greece. He held positions of increasing responsibility across Europe before moving to Pfizer Global Headquarters in New York in 2001 to assume the role of U.S. Group Marketing Director for Animal Health. In 2004, he became Vice President of Business Development and New Products Marketing; supervising Pfizer Animal Health global licensing and acquisition activities, as well as the unit’s R&D portfolio. In 2006, he was appointed Area President of Europe, Africa and Middle East and in 2009, he assumed additional responsibilities for Asia and Pacific.
Albert is a Doctor of Veterinary Medicine and holds a PhD in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. Albert is a member of the following boards: the Pfizer Foundation, which promotes access to quality health care; the Healthcare Leadership Council (HLC), a forum that develops policies, plans, and programs to make affordable, high-quality care accessible to all Americans; and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), an organization that develops effective approaches to health issues.